Harvard Medical School, Brigham and Women’s Hospital, Wyss Institute at Harvard
New technologies can facilitate biomarker discovery by increasing throughput, detecting biomarkers at lower concentrations, and enabling detection of molecules that haven’t been discovered previously. Biomarker discovery, however, is only the beginning of the process. Biomarkers must be validated and methods must be developed for measuring them reproducibly with sufficient throughput to be used in both research and the clinic. The development of new biomarker technology platforms for both discovery and wider implementation involves automation and scaleup to enable biomarker use in research, drug development, and clinical diagnosis.